Ownership and insider activity for Dogwood Therapeutics, Inc. (DWTX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia.
Price
| Price | $1.70 |
| Market Cap | $57M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-16 | De La Rosa Abel | A-Award | 16,800 | $25K |
| 2026-06-16 | Thomas John C | A-Award | 16,800 | $25K |
| 2026-06-16 | Whitley Richard James | A-Award | 16,800 | $25K |
| 2026-06-16 | Keefer David R | A-Award | 16,800 | $25K |
| 2026-03-05 | Grosswald Ralph | A-Award | 82,500 | $236K |
| 2026-03-05 | Walsh Angela | A-Award | 82,500 | $236K |
| 2026-03-05 | Gendreau Roger Michael | A-Award | 82,500 | $236K |
| 2026-03-05 | Duncan Gregory Scott | A-Award | 330,000 | $944K |
| 2025-12-04 | Duncan Gregory Scott | A-Award | 460,000 | $2.8M |
| 2025-12-04 | Walsh Angela | A-Award | 150,000 | $921K |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $30026 | $309384 | $29.8M | $14.0M | $7.0M | $3.3M | $14.8M | $6.5M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $334 | $785 | $324 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $42398 | $315900 | $31.5M | $15.8M | $8.4M | $4.2M | $16.5M | $8.4M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | $222648 | $194931 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | $11.8M | $12.4M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | $65.7M | $69.0M |
| Total Assets | $65935 | $315900 | $31.5M | $15.8M | $8.4M | $4.2M | $94.3M | $90.2M |
| Accounts Payable | $145656 | $35421 | $368905 | $353863 | $573164 | $111913 | $1.2M | $760945 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $1.3M | $1.6M | $1.5M | $1.3M | $1.0M | $358548 | $3.2M | $3.1M |
| Long-term Debt | 0 | $3.6M | 0 | 0 | 0 | 0 | $15.4M | 0 |
| Total Liabilities | $1.3M | $5.3M | $1.5M | $1.3M | $1.0M | $358548 | $30.0M | $15.3M |
| Retained Earnings | -$15.1M | -$17.6M | -$28.0M | -$43.9M | -$56.2M | -$61.5M | -$73.8M | -$108.1M |
| Total Equity | -$1.3M | -$4.9M | $29.9M | $14.5M | $7.3M | $3.8M | $64.3M | $74.9M |
| Total Debt | 0 | $3.6M | 0 | 0 | 0 | 0 | $15.6M | $162604 |
| Net Debt | -$30026 | $3.3M | -$29.8M | -$14.0M | -$7.0M | -$3.3M | $737709 | -$6.4M |
| Working Capital | -$1.3M | -$1.3M | $29.9M | $14.5M | $7.3M | $3.8M | $13.4M | $5.4M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 3.89 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -1.29 |
Profitability
| Return on Equity | -47.85% |
| Return on Invested Capital | -35.62% |
| Return on Assets | -44.77% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: BOLT · BRTX · CLRB · COCP · EDSA · ERNA · EVGN
Explore sector: Healthcare · Biotechnology
More sections of DWTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks